Goldman Sachs’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-523,630
| Closed | -$3.06M | – | 6425 |
|
|
2022
Q4 | $3.06M | Buy |
523,630
+189,551
| +57% | +$997K | ﹤0.01% | 3596 |
|
|
2022
Q3 | $2.24M | Buy |
334,079
+146,591
| +78% | +$889K | ﹤0.01% | 3886 |
|
|
2022
Q2 | $789K | Buy |
+187,488
| New | +$742K | ﹤0.01% | 4791 |
|
|
2021
Q4 | – | Sell |
-15,773
| Closed | -$52K | – | 6810 |
|
|
2021
Q3 | $52K | Sell |
15,773
-78,499
| -83% | -$275K | ﹤0.01% | 6042 |
|
|
2021
Q2 | $398K | Buy |
94,272
+25,687
| +37% | +$109K | ﹤0.01% | 5350 |
|
|
2021
Q1 | $342K | Sell |
68,585
-69,543
| -50% | -$562K | ﹤0.01% | 5351 |
|
|
2020
Q4 | $1.75M | Buy |
138,128
+116,847
| +549% | +$1.33M | ﹤0.01% | 3821 |
|
|
2020
Q3 | $209K | Buy |
21,281
+2,237
| +12% | +$22K | ﹤0.01% | 4894 |
|
|
2020
Q2 | $189K | Sell |
19,044
-22,566
| -54% | -$216K | ﹤0.01% | 4811 |
|
|
2020
Q1 | $368K | Sell |
41,610
-7,920
| -16% | -$78.1K | ﹤0.01% | 4384 |
|
|
2019
Q4 | $457K | Buy |
49,530
+10,073
| +26% | +$71.4K | ﹤0.01% | 4557 |
|
|
2019
Q3 | $232K | Buy |
39,457
+13,144
| +50% | +$139K | ﹤0.01% | 4774 |
|
|
2019
Q2 | $316K | Sell |
26,313
-16,757
| -39% | -$180K | ﹤0.01% | 4599 |
|
|
2019
Q1 | $520K | Buy |
43,070
+28,404
| +194% | +$419K | ﹤0.01% | 4405 |
|
|
2018
Q4 | $184K | Sell |
14,666
-104,148
| -88% | -$1.44M | ﹤0.01% | 4848 |
|
|
2018
Q3 | $1.76M | Sell |
118,814
-6,681
| -5% | -$105K | ﹤0.01% | 3692 |
|
|
2018
Q2 | $2.11M | Buy |
125,495
+34,293
| +38% | +$666K | ﹤0.01% | 3598 |
|
|
2018
Q1 | $2.09M | Sell |
91,202
-7,584
| -8% | -$169K | ﹤0.01% | 3573 |
|
|
2017
Q4 | $2.56M | Buy |
98,786
+65,086
| +193% | +$1.31M | ﹤0.01% | 3578 |
|
|
2017
Q3 | $497K | Buy |
33,700
+16,795
| +99% | +$244K | ﹤0.01% | 5093 |
|
|
2017
Q2 | $236K | Sell |
16,905
-15,444
| -48% | -$228K | ﹤0.01% | 5688 |
|
|
2017
Q1 | $552K | Buy |
32,349
+19,046
| +143% | +$228K | ﹤0.01% | 4930 |
|
|
2016
Q4 | $137K | Sell |
13,303
-3,601
| -21% | -$32.9K | ﹤0.01% | 5992 |
|
|
2016
Q3 | $171K | Buy |
16,904
+4,470
| +36% | +$48.8K | ﹤0.01% | 5922 |
|
|
2016
Q2 | $140K | Buy |
+12,434
| New | +$158K | ﹤0.01% | 5943 |
|
|
2015
Q4 | – | Sell |
-11,679
| Closed | -$219K | – | 7416 |
|
|
2015
Q3 | $219K | Sell |
11,679
-15,277
| -57% | -$260K | ﹤0.01% | 5931 |
|
|
2015
Q2 | $401K | Buy |
26,956
+1,832
| +7% | +$27.9K | ﹤0.01% | 5429 |
|
|
2015
Q1 | $381K | Buy |
25,124
+5,613
| +29% | +$78.3K | ﹤0.01% | 5405 |
|
|
2014
Q4 | $260K | Sell |
19,511
-35,120
| -64% | -$454K | ﹤0.01% | 5929 |
|
|
2014
Q3 | $689K | Sell |
54,631
-2,714
| -5% | -$26.3K | ﹤0.01% | 4988 |
|
|
2014
Q2 | $579K | Sell |
57,345
-9,800
| -15% | -$94.6K | ﹤0.01% | 5179 |
|
|
2014
Q1 | $903K | Buy |
+67,145
| New | +$948K | ﹤0.01% | 4778 |
|
Goldman Sachs's CNCE Position: Q1 2023 in Review
Goldman Sachs sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 523,630 shares — an estimated $3.06M sold.
Goldman Sachs first reported a position in CNCE in Q1 2014 and held it in 32 quarters. The position peaked at $3.06M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Goldman Sachs reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Goldman Sachs sold 523,630 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $3.06M.
- Goldman Sachs first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 32 quarters.
- Goldman Sachs's Concert Pharmaceuticals, Inc. position peaked at $3.06M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.